<DOC>
	<DOC>NCT00311415</DOC>
	<brief_summary>Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children</brief_summary>
	<brief_title>Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children</brief_title>
	<detailed_description>The aim of this study is to investigate the immunogenicity offered by MenCC vaccine when administered in different schedules at different years of life: 2 doses in the first year of life given 2 months apart (at 2 and 4 months of age), with a booster in the second year of life, or 1 dose in the first year of life (at 2 or 6 months of age), with a booster in the second year of life, or only 1 dose in the second year of life.</detailed_description>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy infants known hypersensitivity to any vaccine component significant acute or chronic infections previously ascertained or suspected disease caused by N. meningitidis previous household contact with an individual with a positive culture of N. meningitidis serogroup C</criteria>
	<gender>All</gender>
	<minimum_age>7 Weeks</minimum_age>
	<maximum_age>16 Weeks</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Prevention of Meningococcal Meningitis</keyword>
	<keyword>meningococcal vaccines</keyword>
	<keyword>conjugate</keyword>
	<keyword>immunology</keyword>
	<keyword>infant</keyword>
	<keyword>antibody persistence</keyword>
</DOC>